Cartia XT (Diltiazem Hydrochloride) - Summary

CARTIA XT SUMMARY

CARTIA XT^TM
brand of DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES USP
(ONCE-A-DAY DOSAGE)

Diltiazem hydrochloride is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist).

Diltiazem hydrochloride extended-release capsules USP (once-a-day dosage) are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications.

Diltiazem hydrochloride extended-release capsules USP (once-a-day dosage) is indicated for the management of chronic stable angina and angina due to coronary artery spasm.

CARTIA XT NEWS HIGHLIGHTS

Published Studies Related to Cartia XT (Diltiazem)

Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: the nordic diltiazem study. [2008.07]

Effect of diltiazem and metoprolol on left atrial appendix functions in patients with nonvalvular chronic atrial fibrillation. [2007.03]

Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. [2006.10]

Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. [2006.05]

No gender-associated differences of cyclosporine pharmacokinetics in stable renal transplant patients treated with diltiazem. [2005.10]

more>>

Clinical Trials Related to Cartia XT (Diltiazem)

Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg [Completed]

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg [Completed]

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg [Completed]

Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg [Completed]

The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers [Completed]

more>>